CRISPR/Cas9 Ribonucleoprotein Delivery Enhanced by Lipo-Xenopeptide Carriers and Homology-Directed Repair Modulators: Insights from Reporter Cell Lines
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26094361 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Xianjin Luo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität Munich, Butenandtstrasse 5-13, 81377 Munich, Germany. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, Recombinational DNA Repair, Ribonucleoproteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, European Union, Federal Ministry of Education and Research.
Abstract (Originalsprache)
CRISPR-Cas9 genome editing is a versatile platform for studying and treating various diseases. Homology-directed repair (HDR) with DNA donor templates serves as the primary pathway for gene correction in therapeutic applications, but its efficiency remains a significant challenge. This study investigates strategies to enhance gene correction efficiency using a T-shaped lipo-xenopeptide (XP)-based Cas9 RNP/ssDNA delivery system combined with various HDR enhancers. Nu7441, a known DNA-PKcs inhibitor, was found to be most effective in enhancing HDR-mediated gene correction. An over 10-fold increase in HDR efficiency was achieved by Nu7441 in HeLa-eGFPd2 cells, with a peak HDR efficiency of 53% at a 5 nM RNP concentration and up to 61% efficiency confirmed by Sanger sequencing. Surprisingly, the total gene editing efficiency including non-homologous end joining (NHEJ) was also improved. For example, Nu7441 boosted exon skipping via NHEJ-mediated splice site destruction by 30-fold in a DMD reporter cell model. Nu7441 modulated the cell cycle by reducing cells in the G1 phase and extending the S and G2/M phases without compromising cellular uptake or endosomal escape. The enhancement in genome editing by Nu7441 was widely applicable across several cell lines, several Cas9 RNP/ssDNA carriers (LAF-XPs), and also Cas9 mRNA/sgRNA/ssDNA polyplexes. These findings highlight a novel and counterintuitive role for Nu7441 as an enhancer of both HDR and total gene editing efficiency, presenting a promising strategy for Cas9 RNP-based gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität Munich, Butenandtstrasse 5-13, 81377 Munich, Germany.
- Center for Nanoscience (CeNS), LMU Munich, 80799 Munich, Germany.
- CNATM-Cluster for Nucleic Acid Therapeutics Munich, 81377 Munich, Germany.
ORCID-Profile: Ernst Wagner
Förderung
- Deutsche Forschungsgemeinschaft
- European Union
- Federal Ministry of Education and Research
- China Scholarship Council
- German Research Foundation
- BMBF Cluster for Future
Zitieren
APA
Luo, X., Weidinger, E., Burghardt, T., Höhn, M., & Wagner, E. (2025). CRISPR/Cas9 Ribonucleoprotein Delivery Enhanced by Lipo-Xenopeptide Carriers and Homology-Directed Repair Modulators: Insights from Reporter Cell Lines. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094361
Vancouver
Luo X, Weidinger E, Burghardt T, Höhn M, Wagner E. CRISPR/Cas9 Ribonucleoprotein Delivery Enhanced by Lipo-Xenopeptide Carriers and Homology-Directed Repair Modulators: Insights from Reporter Cell Lines. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094361
BibTeX
@article{Luo2025,
author = {Luo, Xianjin and Weidinger, Eric and Burghardt, Tobias and Höhn, Miriam and Wagner, Ernst},
title = {CRISPR/Cas9 Ribonucleoprotein Delivery Enhanced by Lipo-Xenopeptide Carriers and Homology-Directed Repair Modulators: Insights from Reporter Cell Lines},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26094361}
}
EUVIMED